Page last updated: 2024-09-05

sb 203580 and palbociclib

sb 203580 has been researched along with palbociclib in 5 studies

Compound Research Comparison

Studies
(sb 203580)
Trials
(sb 203580)
Recent Studies (post-2010)
(sb 203580)
Studies
(palbociclib)
Trials
(palbociclib)
Recent Studies (post-2010) (palbociclib)
3,48941,137911126864

Protein Interaction Comparison

ProteinTaxonomysb 203580 (IC50)palbociclib (IC50)
Chain B, Cell division protein kinase 6Homo sapiens (human)0.015
Chain B, Cell division protein kinase 6Homo sapiens (human)0.015
Cyclin-T1Homo sapiens (human)1.5085
Cyclin-KHomo sapiens (human)1.207
Cyclin-dependent kinase 1Homo sapiens (human)9.8
Cyclin-dependent kinase 4Homo sapiens (human)0.0109
G2/mitotic-specific cyclin-B1Homo sapiens (human)9.8
Cyclin-A2Homo sapiens (human)2.2042
AcetylcholinesteraseMus musculus (house mouse)0.021
G1/S-specific cyclin-D1Homo sapiens (human)0.0115
G1/S-specific cyclin-E1Homo sapiens (human)9.15
Cyclin-dependent kinase 2Homo sapiens (human)4.1887
G1/S-specific cyclin-D2Homo sapiens (human)0.0127
G1/S-specific cyclin-D3Homo sapiens (human)0.0194
Receptor-type tyrosine-protein kinase FLT3Homo sapiens (human)3.48
Cyclin-dependent kinase 9Homo sapiens (human)1.1821
Tyrosine-protein kinase JAK3Homo sapiens (human)0.0631
Cyclin-dependent kinase 6Homo sapiens (human)0.018

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (60.00)24.3611
2020's2 (40.00)2.80

Authors

AuthorsStudies
Hajduk, PJ; Johnson, EF; Kifle, L; Merta, PJ; Metz, JT; Soni, NB1
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Bharate, SB; Raghuvanshi, R1
Caballero, E; García-Cárceles, J; Gil, C; Martínez, A1
Bae, SC; Chi, XZ; Hyun, JW; Ito, Y; Jang, JW; Kim, DM; Lee, JW; Lee, YS; Park, IY; Park, TG; Song, SH1

Reviews

1 review(s) available for sb 203580 and palbociclib

ArticleYear
Kinase Inhibitors as Underexplored Antiviral Agents.
    Journal of medicinal chemistry, 2022, 01-27, Volume: 65, Issue:2

    Topics: Animals; Antiviral Agents; Drug Repositioning; Humans; Protein Kinase Inhibitors; Virus Diseases; Viruses

2022

Other Studies

4 other study(ies) available for sb 203580 and palbociclib

ArticleYear
Navigating the kinome.
    Nature chemical biology, 2011, Volume: 7, Issue:4

    Topics: Drug Design; Pharmacogenetics; Protein Kinases; Proteome; Systems Biology

2011
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
    Journal of medicinal chemistry, 2022, 01-27, Volume: 65, Issue:2

    Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases

2022
RUNX3 regulates cell cycle-dependent chromatin dynamics by functioning as a pioneer factor of the restriction-point.
    Nature communications, 2019, 04-23, Volume: 10, Issue:1

    Topics: Animals; Butadienes; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Chromatin; Chromatin Assembly and Disassembly; Core Binding Factor Alpha 3 Subunit; Cyclin-Dependent Kinase 4; Drosophila melanogaster; Epithelial Cells; Gene Expression Regulation; HEK293 Cells; Histone-Lysine N-Methyltransferase; Humans; Imidazoles; MAP Kinase Kinase 1; MAP Kinase Kinase 4; Myeloid-Lymphoid Leukemia Protein; Nitriles; p38 Mitogen-Activated Protein Kinases; Piperazines; Polycomb-Group Proteins; Protein Kinase Inhibitors; Pyridines; ras Proteins; RNA, Small Interfering; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases

2019